News | November 06, 2007

Stem Cells Injected Into Heart Boost Pumping Ability After Heart Attack

November 7, 2007 - Patients’ own stem cells injected into their hearts after treatment for an ST elevation heart attack improved their hearts’ improved pumping ability, researchers reported during a late-breaking special session on stem cell research at the American Heart Association Scientific Sessions 2007.

In the IM-BMC randomized, double-blind trial, researchers assessed the safety and efficacy of injecting sufferers’ own stem cells into their hearts. The patients had been initially treated with clot-busting drugs, followed by percutaneous coronary intervention (PCI).

Past studies have yielded mixed results regarding the effect of injecting patients’ own bone marrow cells to treat reduced heart function, irregular heartbeat and re-blockages in stented arteries.

Researchers enrolled 80 patients who had had an ST elevation heart attack and they were randomly selected to receive intracoronary bone marrow or placebo injections in the heart or placebo injections. These procedures were performed 0-3 days after bone marrow cell (BMC) delivery and repeated six months after the STEMI.

At six months, the patients randomized to BMC therapy (n=33) showed a significant increase of their global ejection fraction (EF) measured by angiography (from 59±8% to 67±9, p

Researchers observed no differences between the groups in the measures of heart rate variability, signal-averaged electrocardiogram, prevalence of positive T-wave alternans tests, or the minimal lumen diameter and area of the stented culprit lesion.

“This study shows intracoronary BMC-therapy is associated with an improvement of global left ventricular function and no adverse effects on arrhythmia risk profile or restenosis of the stented coronary lesions in patients treated with thrombolytic therapy followed by PCI of an acute ST elevation heart attack,” said Heikki Huikuri, M.D., lead investigator and professor of medicine and director of cardiology sector at the University of Oulu Hospital in Oulu, Finland.

Support for this study was provided by the Finnish Academy of Science, Helsinki, Finland and Boston Scientific Inc.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information: www.americanheart.org

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init